Search Job Title Only
News By Subject
News by Disease
News By Date
Get Our FREE
Wants More Info On
's Female Libido Pill
2/11/2014 8:34:00 AM
The U.S. Food and Drug Administration has denied an appeal by Sprout Pharmaceuticals to approve its experimental drug for low female sexual desire but offered a potential pathway to approval, the company said on Tuesday. The FDA has asked for three additional studies, two to test the drug's interaction with other drugs, and a third to simulate driving since nearly 10 percent of women in clinical trials became sleepy while taking the drug, flibanserin. Privately held Sprout said it welcomed the FDA's guidance and views it as "a significant step" toward approving flibanserin, a once-a-day treatment for hypoactive sexual desire disorder (HSDD).
Help employers find you! Check out all the
post your resume
Hematogenix Laboratory Services
Approved THxID®-BRAF Companion Diagnostic Testing Services In The U.S.
RedHill Biopharma Ltd.
(RDHL)'s Acute Migraine Drug
Approvals -- Informative Or Irresponsible?
No Serious Side Effects With
Merck & Co., Inc.
(MRK)'s Experimental Allergy Pill —
Over-The-Counter Clearance For Its Heart Monitor
AMAG Pharmaceuticals, Inc.
(AMAG) Drops As The
Turns Down Application For Iron Deficiency Drug Feraheme®
Receives Clear Guidance From
On Path Forward To Resubmit New Drug Application For Flibanserin, The First Potential Medical Treatment For Hypoactive Sexual Desire Disorder In Premenopausal Women
Provides Regulatory And Commercial Update On The Label Indication For Zestra® For Female Sexual Desire Disorder ("FSDD") From
's Female Libido Drug Gets No Love From The
, Company Plans To Appeal
Tries Again With "Pink Viagra"
comments powered by Disqus.
comments powered by
Food and Drug Administration (FDA)
Clinical - BLA/NDA/ANDA
Female sexual dysfunction